Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women

Giovanna Iantevi Ghelfond, MD, Fernanda Santos, MD, Fernanda S Seguro, MD, Andre Abdo, MD, Thales Pereira, MD, Felipe VR Maciel, MD, Lucas BO Alves, PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MDPhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142098

Published: 2020

Journal Articles

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

Antonio Adolfo Guerra Soares Brandão, MD, Giancarlo Fatobene, MD, Andre Abdo, MD, Luis Alberto de Padua Covas Lage, MD PhD, Israel Bendit, MD PhD, Luciana Nardinelli, MSc, Sheila Aparecida Coelho de Siqueira, MD PhD, Debora Levy, MSc, PhD, Juliana Pereira, MD PhD, Eduardo M Rego, MDPhD, Vanderson Rocha, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142617

Published: 2020

Journal Articles

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-140697

Published: 2020

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Lidiane Inês Da Rosa, MD, Wellington Fernandes da Silva, MD, Andre Abdo, MD, Eduardo M Rego, MD PhD, Vanderson Rocha, MD PhD, Juliana Pereira, MD PhD

Blood (2019) 134 (Supplement_1): 5284.

https://doi.org/10.1182/blood-2019-126307

Published: 2019

Journal Articles

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

Andre Abdo, MD, Carla Maria Boquimpani, MD, Douglas Vivona, PhD, Viviane Silveira Leite, BSC, Alisson L. Matsuo, PhD, Vanessa Teich, BSC, Israel Bendit, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2018-99-119200

Published: 2018

NARROW

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only